Nautilus Biotechnology IncNASDAQ:NAUT
No Matches were found for
- LAST PRICE2.9099
- TODAY'S CHANGE (%)0.0599 (2.1018%)
- Bid / Lots2.9100/ 6
- Ask / Lots2.9200/ 2
- Open / Previous Close2.8900 / 2.8500
- Day Range
- 52 Week Range
- Volume22,313
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
Select an index
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NAUT |
|---|---|---|
| 09:32 ET | 546 | 2.89 |
| 10:24 ET | 300 | 2.86 |
| 10:39 ET | 100 | 2.875 |
| 10:44 ET | 200 | 2.87 |
| 10:48 ET | 163 | 2.88 |
| 10:55 ET | 100 | 2.8801 |
| 11:06 ET | 842 | 2.88 |
| 11:09 ET | 100 | 2.895 |
| 11:20 ET | 100 | 2.88 |
| 11:38 ET | 1307 | 2.89 |
| 12:02 ET | 3464 | 2.9 |
| 12:16 ET | 200 | 2.89 |
| 12:34 ET | 100 | 2.88 |
| 01:03 ET | 100 | 2.905 |
| 01:06 ET | 134 | 2.908 |
| 01:17 ET | 100 | 2.91 |
| 01:21 ET | 200 | 2.91 |
| 01:26 ET | 100 | 2.93 |
| 01:30 ET | 100 | 2.925 |
| 01:32 ET | 2500 | 2.9208 |
| 01:33 ET | 2454 | 2.92 |
| 01:39 ET | 104 | 2.915 |
| 01:53 ET | 921 | 2.92 |
| 01:55 ET | 100 | 2.93 |
| 02:06 ET | 100 | 2.93 |
| 02:11 ET | 100 | 2.93 |
| 02:20 ET | 100 | 2.93 |
| 02:27 ET | 200 | 2.92 |
| 02:29 ET | 227 | 2.9185 |
| 02:33 ET | 100 | 2.9 |
| 02:36 ET | 200 | 2.905 |
| 02:51 ET | 100 | 2.91 |
| 02:58 ET | 600 | 2.92 |
| 03:05 ET | 243 | 2.925 |
| 03:09 ET | 100 | 2.93 |
| 03:12 ET | 237 | 2.929 |
| 03:18 ET | 100 | 2.92 |
| 03:23 ET | 871 | 2.9099 |
Sep 17, 2024
Press Release: Nautilus Biotechnology Appoints Mass Spectrometry Leader Ken Suzuki as Chief Marketing Officer, from 8:00AM ET on Tuesday Sep 17, 2024 by Dow Jones
8:00AM ET on Tuesday Sep 17, 2024 by Dow JonesNautilus Biotechnology Appoints Mass Spectrometry Leader Ken Suzuki as Chief Marketing Officer, from 8:00AM ET on Tuesday Sep 17, 2024 by Dow Jones
8:00AM ET on Tuesday Sep 17, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Nautilus Biotechnology Inc | 357.4M | -5.2x | --- |
GH Research PLC | 364.2M | 0.0x | --- |
Biomea Fusion Inc | 346.5M | -2.5x | --- |
Eliem Therapeutics Inc | 335.3M | -2.3x | --- |
Monte Rosa Therapeutics Inc | 329.0M | -2.3x | --- |
Lyell Immunopharma Inc | 389.1M | -1.8x | --- |
Company Information
No data available
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $357.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 125.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.02 |
EPS | $-0.56 |
Book Value | $2.12 |
P/E Ratio | -5.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
